Invesco Ltd. Makes New Investment in Cellebrite DI Ltd. (NASDAQ:CLBT)

Invesco Ltd. purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 1,484,322 shares of the company’s stock, valued at approximately $32,700,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in CLBT. JPMorgan Chase & Co. grew its position in Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after acquiring an additional 75,092 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Cellebrite DI by 65.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after purchasing an additional 62,320 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cellebrite DI during the 4th quarter worth $9,995,000. State Street Corp increased its position in shares of Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock worth $7,472,000 after purchasing an additional 30,052 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Cellebrite DI by 2.6% in the 4th quarter. New York State Common Retirement Fund now owns 189,599 shares of the company’s stock valued at $4,177,000 after buying an additional 4,838 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, Lake Street Capital boosted their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Stock Down 0.7 %

Cellebrite DI stock opened at $18.90 on Friday. The company’s 50 day moving average is $19.10 and its two-hundred day moving average is $20.04. The firm has a market cap of $4.53 billion, a PE ratio of -13.60, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.